Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 4/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.67 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.67 |
| ▸ | GCK | P35557 | 1/20 | 0.67 |
| ▸ | GRM5 | P41594 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | SCD | O00767 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24101768 | 0.89 | MAPT (0.79) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL17988256 | 0.83 | RAB9A (1.00) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL18236206 | 0.83 | RAB9A (0.74) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL22125449 | 0.81 | SMARCA2 (1.00) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL10816647 | 0.80 | RAB9A (0.71) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL2682054 | 0.78 | KMT2A (1.00) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL5215989 | 0.77 | MAPT (0.63) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL4740825 | 0.77 | KMT2A (0.77) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL123330 | 0.77 | RAB9A (0.64) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL21066417 | 0.76 | MAPT (0.67) | MAPTKMT2AMEN1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAPT 4151/4885KMT2A 1905/4885MEN1 4843/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAPT 4151/4885KMT2A 1905/4885MEN1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.